Andre Turenne, Voyager CEO

Voy­ager CEO An­dre Turenne re­signs amid set­backs, as the biotech piv­ots back to dis­cov­ery

Af­ter three years and a se­ries of set­backs, CEO and Pres­i­dent An­dre Turenne will step down from Voy­ager Ther­a­peu­tics, as the be­lea­guered com­pa­ny an­nounced they will piv­ot its fo­cus to ear­ly, dis­cov­ery-stage ef­forts. The com­pa­ny’s CMO and R&D chief, Omar Khwa­ja, al­so stepped down af­ter two years at the biotech.

Voy­ager said on­ly that Turenne will leave to “pur­sue oth­er op­por­tu­ni­ties” and Khwa­ja found a new op­por­tu­ni­ty in Eu­rope, but the move comes as Voy­ager $VY­GR finds it­self as a cross­roads. One of the hand­ful of com­pa­nies to launch with great fan­fare amid gene ther­a­py’s ear­ly-2010s resur­gence, Voy­ager won back­ing from Third Rock to take the modal­i­ty out of rare dis­eases and in­to com­mon neu­ro­log­i­cal con­di­tions like Parkin­son’s and Alzheimer’s. Sanofi signed on ear­ly with a near­ly $1 bil­lion col­lab­o­ra­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.